Nebido (Testosterone Undecanoate)

Testosterone undecanoate is an esterified form of testosterone that, after intramuscular injection, is slowly hydrolyzed by esterases in the bloodstream, releasing free testosterone. The liberated hormone binds to intracellular androgen receptors, forming a complex that translocates to the nucleus and modulates gene transcription, producing androgenic and anabolic effects on target tissues such as muscle, bone, and the reproductive system.

The dosing regimen for Nebido is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, baseline testosterone levels, and response to therapy. Typically, the product is supplied in 1000 mg vials for intramuscular injection, and the prescribing physician decides the injection interval and any dose adjustments.

Nebido is intended for use in adult males and is not indicated for women. Its safety in pregnancy or while breastfeeding has not been established, and the product is classified as contraindicated for use in pregnant or nursing women due to the potential for fetal or neonatal androgen exposure.

To place an order, submit an enquiry on the Nebido product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After validation, the sales team provides pricing, availability, shipping details—including cold‑chain logistics if needed—and assists with import documentation.

Nebido provides a long‑acting testosterone formulation that requires fewer injections—typically every 10‑14 weeks—compared with shorter‑acting intramuscular preparations such as testosterone enanthate or cypionate, which may need administration every 2‑4 weeks. This extended dosing interval can improve patient convenience and adherence, while delivering comparable androgenic and anabolic effects.

Nebido vials should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect from light and moisture. They must not be frozen or shaken. Prior to administration, the vial should be inspected for particulate matter and any signs of contamination, and handled using aseptic technique.

Nebido is administered by deep intramuscular injection, usually into the gluteal muscle. The injection should be performed by a qualified healthcare professional using aseptic technique. The volume and injection site are determined by the prescriber, and the product may be reconstituted according to the manufacturer’s instructions before administration.

The most serious potential risks of Nebido include polycythemia, which can increase the likelihood of thrombosis; cardiovascular events such as myocardial infarction or stroke; and rare cases of hepatotoxicity. Patients should be monitored regularly for hematocrit levels, cardiovascular health, and liver function to detect these complications early.

Nebido is contraindicated in individuals with known hypersensitivity to testosterone undecanoate or any excipients, in patients with prostate or breast cancer, in those with severe untreated sleep apnea, and in women who are pregnant or breastfeeding. Caution is also advised for patients with uncontrolled heart failure, severe liver disease, or a history of thromboembolic disorders.